MediWound announces peer-review publication of EscharEx

MediWound announced the publication of a peer-reviewed paper, titled “An Open-label, Proof of Concept Study, Assessing the Effects of Bromelain-Based Enzymatic Debridement on Biofilm and Microbial Loads in Patients with Venous Leg and Diabetic Foot Ulcers” in the December 2023 issue of WOUNDS Journal. The paper highlights results from a Phase II study, which explored the mechanism of action of EscharEx, a novel bromelain based enzymatic debridement agent, in 12 patients with either venous leg ulcers or diabetic foot ulcers. Results show that EscharEx not only effectively debrides wounds, but also reduces biofilm and bacterial load in both VLUs and DFUs. Key findings: 70% of the patients that completed the study achieved complete debridement within a median time of 5.5 days. An average reduction of 35% in wound size was achieved by the end of the 2-week follow-up period. In all six patients positive for biofilm at baseline, EscharEx reduced the biofilm to a single individual or undetectable microorganisms, by the end of treatment based on tissue biopsies. Bacterial load was reduced by 64% following treatment with EscharEx based on a fluorescence imaging device. EscharEx was shown to be safe and well tolerated.